Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Reimbursement Limits Threaten Drug Access

May 22, 2014

Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.

Obama Policies Reshape Pharma Marketing

Apr 10, 2014

Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.

Manufacturers Struggle with FDA's "Breakthrough Drug" Development

Accelerated testing and production create challenges in documenting product quality.
Mar 21, 2014

Accelerated testing and production create challenges in documenting product quality, writes Jill Wechsler.

Data disclosure, integrity challenge pharma

Mar 1, 2014

Transparency initiatives are multiplying, affecting research, marketing and compliance.

The Push for Transparency: Risks, Costs, and Concerns

Feb 26, 2014

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.

Drug Coverage, Costs Under Scrutiny

Feb 1, 2014

Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

US Pharma Challenges 2014

Jan 8, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing in the U.S. in 2014, writes Jill Wechsler.

Pharma Challenges for 2014

Jan 1, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing

FDA Pursues Delicate Balancing Act

Dec 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

ADVERTISEMENT

Click here